A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

NCT01877382 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Lymphoma

Interventions

DRUG: Milademetan
DRUG: Milademetan

Sponsor

Daiichi Sankyo